Sophiris Bio (SPHS) Reports Q1 Loss of $0.13/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Sophiris Bio (SPHS) Reports Q1 Loss of $0.13/Share

Sophiris Bio Reports First Quarter 2016 Financial Results and Key Business Highlights

May 16, 2016 4:01 PM EDT

SAN DIEGO and VANCOUVER, British Columbia, May 16, 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three months ended March 31, 2016.

Business Highlights:

On May 12, 2016, the Company announced the engagement Oppenheimer & Co. Inc. as its financial advisor to assist with the evaluation of various strategic alternatives. On May 11, 2016, the Company announced the closing of a public offering of common shares and warrants in which the... More